Get the Stockscreener App
9.34
2.64%
0.24
After Hours:
9.34
Neogenomics Inc stock is traded at $9.34, with a volume of 9.45M.
It is up +2.64% in the last 24 hours and up +17.34% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$9.10
Open:
$9.12
24h Volume:
9.45M
Relative Volume:
3.17
Market Cap:
$1.21B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-15.06
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
+2.64%
1M Performance:
+17.34%
6M Performance:
+0.21%
1Y Performance:
-30.97%
1-Day Range:
$9.10
$9.62
1-Week Range:
$8.68
$9.62
52-Week Range:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
9.34 | 1.18B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
How to track smart money flows in NeoGenomics Inc.Buy Signal & Reliable Price Breakout Signals - newser.com
How hedge fund analytics apply to NeoGenomics Inc. stockJuly 2025 Final Week & Community Consensus Stock Picks - newser.com
Is NeoGenomics Inc. stock bottoming outWeekly Risk Report & Reliable Volume Spike Alerts - newser.com
Will NeoGenomics Inc. stock gain from government policiesJuly 2025 Highlights & Real-Time Market Sentiment Alerts - newser.com
Forecasting NeoGenomics Inc. price range with options dataJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Is NeoGenomics Inc. (NG9) stock good for wealth creation2025 Geopolitical Influence & Growth Focused Entry Reports - newser.com
Volatility clustering patterns for NeoGenomics Inc.July 2025 Levels & Verified Swing Trading Watchlist - newser.com
Is NeoGenomics Inc. stock affected by interest rate hikesJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Regression analysis insights on NeoGenomics Inc. performanceExit Point & AI Driven Stock Movement Reports - newser.com
Earnings visualization tools for NeoGenomics Inc.2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - newser.com
NeoGenomics rallies after court win in Natera patent dispute - MSN
NeoGenomics' (NEO) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
What catalysts could drive NeoGenomics Inc. stock higher2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
Measuring NeoGenomics Inc.’s beta against major indicesJuly 2025 Earnings & Verified Momentum Watchlists - newser.com
Volume spikes in NeoGenomics Inc. stock – what they meanJobs Report & Verified Chart Pattern Signals - newser.com
Is NeoGenomics Inc. forming a bottoming baseEarnings Recap Report & Weekly Watchlist for Consistent Profits - newser.com
Is NeoGenomics Inc a good long term investmentMarket Liquidity Analysis & Options Trading Analysis Tools - earlytimes.in
United States Pathological Examination Market Growth & - openPR.com
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025 - BioSpace
NeoGenomics Inc Stock Analysis and ForecastTrading Volume Surges & Outstanding Portfolio Tips - earlytimes.in
What valuation multiples suggest for NeoGenomics Inc. stock2025 Buyback Activity & Safe Capital Growth Stock Tips - newser.com
Piper Sandler Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
NeoGenomics (NASDAQ:NEO) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know - The Globe and Mail
NeoGenomics (NASDAQ:NEO) Trading 9.1% HigherHere's What Happened - MarketBeat
Strategies to average down on NeoGenomics Inc.2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com
NeoGenomics (NASDAQ:NEO Shareholders Incur Further Losses as Stock Declines 7.5% This Week, Taking Five-year Losses to 79% - 富途牛牛
Opportunities in the Booming AI in Bioinformatics Market: A $26+ Billion Industry by 2029 Led by Thermo Fisher Scientific, Eurofins Scientific, Dassault Systemes, Illumina and NeoGenomics Laboratories - Yahoo
NeoGenomics (NEO): Exploring Current Valuation After Recent Share Price Volatility - Yahoo Finance
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
United States Clinical Laboratory Services Market Poised - openPR.com
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neogenomics Inc Stock (NEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zook Anthony P. | Chief Executive Officer |
Aug 06 '25 |
Buy |
5.58 |
17,900 |
99,954 |
38,066 |
| Williams Felicia | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
7,160 |
0 |
7,160 |
| KANOVSKY STEPHEN M | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
52,344 |
| Kelly Michael Aaron | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
44,009 |
| TETRAULT LYNN A. | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
73,652 |
| Floegel Elizabeth | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Gunn Neil | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
28,100 |
| Zook Anthony P. | Chief Executive Officer |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Perez David Brian | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
33,890 |
| Kelly Michael Aaron | Director |
May 27 '25 |
Buy |
7.60 |
5,000 |
38,000 |
5,000 |
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):